Valneva Aktie

4,44 EUR +0,19 EUR +4,57 %

17:40:32

FSE

2,41 EUR -0,92 EUR -27,61 %

04.07.2025

LSE

Valneva jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.750,12 Mio. EUR

Div. Rendite0,00%

WKNA0MVJZ

ISINFR0004056851

SymbolINRLF

Valneva Aktien News

Sortieren:Datum Meistgelesen

05.06.25GlobeNewswireValneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

05.06.25GlobeNewswire[Valneva SE] Declaration of shares and voting rights - May 2025

04.06.25GlobeNewswireValneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

WerbungValneva-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

26.05.25GlobeNewswireValneva to Participate at U.S. and European Investor Conferences in June

12.05.25GlobeNewswireValneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

07.05.25GlobeNewswireVALNEVA Declaration of shares and voting rights: April 30, 2025

07.05.25GlobeNewswireValneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

07.05.25GlobeNewswireValneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

26.04.25GlobeNewswireValneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

18.04.25GlobeNewswireValneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

16.04.25GlobeNewswireValneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

14.04.25GlobeNewswireValneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country

09.04.25GlobeNewswireValneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

03.04.25GlobeNewswireValneva SE Shareholding Declaration - March 2025

01.04.25GlobeNewswireValneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above

31.03.25GlobeNewswireValneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA

26.03.25GlobeNewswireValneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program

25.03.25GlobeNewswireValneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

24.03.25GlobeNewswireValneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion

20.03.25GlobeNewswireValneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

05.03.25GlobeNewswireVALNEVA Declaration of shares and voting rights: February 28, 2025

03.03.25GlobeNewswireValneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

28.02.25GlobeNewswireValneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®

18.02.25GlobeNewswireValneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook

06.02.25GlobeNewswireShareholding declaration Valneva SE - January 2025

05.02.25GlobeNewswireValneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®

30.01.25GlobeNewswireValneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million

22.01.25GlobeNewswireValneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision

20.01.25GlobeNewswireValneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine

06.01.25GlobeNewswireValneva to Meet with Investors during the J.P. Morgan Healthcare Conference

03.01.25GlobeNewswireVALNEVA Declaration of shares and voting rights: December 31, 2024

19.12.24GlobeNewswireValneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India

05.12.24GlobeNewswireVALNEVA - Declaration of shares and voting rights: November 30, 2024

04.12.24GlobeNewswireValneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal

03.12.24GlobeNewswireValneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

26.11.24GlobeNewswireValneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA

13.11.24GlobeNewswireValneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

12.11.24GlobeNewswireValneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

07.11.24GlobeNewswireValneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

06.11.24GlobeNewswireVALNEVA - Declaration of shares and voting rights: October 31, 2024

Valneva News

Valneva News: auf dieser Seite finden Sie alle Valneva News und Nachrichten zur Valneva Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Valneva News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Valneva News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.